Government of Iran Report issue

Government Phase 1 Phase 2 Phase 3
Founded: Tehran Iran (Islamic Republic of) (1979)

Organization Overview

First Clinical Trial
2018
NCT03329664
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Ministry of Health and Medical Education | National Institute for Medical Research Development | National Institute for Medical Research Development (NIMAD), Iran | National Institute of Medical Research Development (NIMAD), Iran

Active Ingredients

Drugs in Phase 3 Trials (2)

hydralazine (apresoline) (1 trial)

wharton's jelly mesenchymal stem cells (1 trial)

Drugs in Phase 2 Trials (3)

cytokine induced killer cells (1 trial)

melatonin (1 trial)

trehalose (1 trial)

Drugs in Phase 1 Trials (1)

cd19 car-t cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 2)

Colonic Neoplasms (Phase 2)

Heart Failure (Phase 2)

Inflammation (Phase 2)

Leukemia (Phase 1)

Leukemia, Lymphoid (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 6